Scott A. Armstrong, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘03-‘08) of Dana-Farber Cancer Institute and Children’s Hospital Boston, and colleagues, reported the role of a protein called β-catenin in chronic myeloid leukemia (CML) stem cells. They demonstrated that reducing β-catenin in combination with treatment with Gleevec/imatinib decreases CML stem cells in mice, without harming healthy cells. These findings, published in the journal Cell Stem Cell, suggest that this combination therapy may prevent recurrence of AML disease in patients.